Bottom line
Is PBE a good fund? The bottom line
PBE is an actively managed technology sector ETF from Invesco.
It charges 0.59% — about $59 a year on every $10,000 invested, cheaper than 71% of technology sector funds we track.
It returned +24.7% over one year, +3.4% a year over five years, +5.2% a year over ten (as of Dec 31, 2025, per its prospectus).
With $282 million in net assets and 33 holdings, its largest position is Invesco Private Prime Fund (12.9%) and the top 10 make up 56.8% of the portfolio.
What to watch
- Concentrated: top 10 holdings are 56.8% of assets
- High turnover (103% a year) can mean more taxable distributions
Updated Nov 19, 2026
What PBE invests in
The Invesco Biotechnology & Genome ETF (the Fund) seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome Intellidex Index (the Underlying Index).
The Fund is an index fund that seeks to track the investment results of the Underlying Index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC (ICE Data or the Index Provider) compiles and maintains the Underlying Index, which is composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, and are companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research. These companies may include biopharmaceutical companies that actively participate in the research and development, animal testing and partial human testing phases of drug development, typically using biotechnological techniques that…
From the fund's prospectus (filed Aug 27, 2026).
PBE performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| PBE | +24.7% | +3.4% | +5.2% |
| Technology Sector median | +24.0% | +10.0% | +16.7% |
Source: Fund prospectus, as of Dec 31, 2025
What PBE costs
On a $10,000 investment, PBE's 0.59% expense ratio costs about $59 a year. The prospectus estimates $738 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.
PBE top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Invesco Private Prime Fund | 12.89% |
| 2 | Regeneron Pharmaceuticals, Inc. | 5.47% |
| 3 | Amgen Inc. | 5.22% |
| 4 | CareDx, Inc. | 5.04% |
| 5 | Vertex Pharmaceuticals Inc. | 4.99% |
| 6 | Invesco Private Government Fund | 4.97% |
| 7 | Royalty Pharma PLC | 4.94% |
| 8 | Biogen Inc. | 4.79% |
| 9 | Gilead Sciences, Inc. | 4.43% |
| 10 | United Therapeutics Corp. | 4.08% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 56.8% of the fund. See all top 25 holdings and asset mix →